SDC1 and Miyoshi myopathy: To further evaluate the therapeutic potential of combo therapy, we treated ex vivo cultures of CD138+ plasma cells from nine newly diagnosed MM patients (Table 1) and PBMCs from six healthy donors with CFZ/SP2509 or single agents.